Literature DB >> 17132774

The unstoppable connexin43 carboxyl-terminus: new roles in gap junction organization and wound healing.

Robert G Gourdie1, Gautam S Ghatnekar, Michael O'Quinn, Matthew J Rhett, Ralph J Barker, Ching Zhu, Jane Jourdan, Andrew W Hunter.   

Abstract

Intercellular connectivity mediated by gap junctions (GJs) composed of connexin43 (Cx43) is critical to the function of excitable tissues such as the heart and brain. Disruptions to Cx43 GJ organization are thought to be a factor in cardiac arrhythmias and are also implicated in epilepsy. This article is based on a presentation to the 4th Larry and Horti Fairberg Workshop on Interactive and Integrative Cardiology and summarizes the work of Gourdie and his lab on Cx43 GJs in the heart. Background and perspective of recently published studies on the function of Cx43-interacting protein zonula occludens-(ZO)-1 in determining the organization of GJ plaques are provided. In addition how a peptide containing a PDZ-binding sequence of Cx43, developed as part of the work on cardiac GJ organization is also described, which has led to evidence for novel and unexpected roles for Cx43 in modulating healing following tissue injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132774     DOI: 10.1196/annals.1380.005

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

Review 1.  Cardiac to cancer: connecting connexins to clinical opportunity.

Authors:  Christina L Grek; J Matthew Rhett; Gautam S Ghatnekar
Journal:  FEBS Lett       Date:  2014-03-04       Impact factor: 4.124

Review 2.  Therapeutic strategies targeting connexins.

Authors:  Dale W Laird; Paul D Lampe
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

Review 3.  Gap junctional regulation of signal transduction in bone cells.

Authors:  Atum M Buo; Joseph P Stains
Journal:  FEBS Lett       Date:  2014-01-28       Impact factor: 4.124

4.  Topical administration of a connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: A multicenter, randomized trial.

Authors:  Christina L Grek; G M Prasad; Vijay Viswanathan; David G Armstrong; Robert G Gourdie; Gautam S Ghatnekar
Journal:  Wound Repair Regen       Date:  2015-04-29       Impact factor: 3.617

5.  Bone marrow-derived mesenchymal stem cell attenuates skin fibrosis development in mice.

Authors:  Yan Wu; Sha Huang; Jirigala Enhe; Kui Ma; Siming Yang; Tongzhu Sun; Xiaobing Fu
Journal:  Int Wound J       Date:  2013-02-15       Impact factor: 3.315

Review 6.  Embryonic wound healing: a primer for engineering novel therapies for tissue repair.

Authors:  Katherine E Degen; Robert G Gourdie
Journal:  Birth Defects Res C Embryo Today       Date:  2012-09

7.  Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding.

Authors:  Gautam S Ghatnekar; Michael P O'Quinn; L Jane Jourdan; Abhijit A Gurjarpadhye; Robert L Draughn; Robert G Gourdie
Journal:  Regen Med       Date:  2009-03       Impact factor: 3.806

8.  Connexin43 modulates cell polarity and directional cell migration by regulating microtubule dynamics.

Authors:  Richard Francis; Xin Xu; Hyunsoo Park; Chin-Jen Wei; Stephen Chang; Bishwanath Chatterjee; Cecilia Lo
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

9.  Targeting Cx43 and N-cadherin, which are abnormally upregulated in venous leg ulcers, influences migration, adhesion and activation of Rho GTPases.

Authors:  Ariadna Mendoza-Naranjo; Peter Cormie; Antonio E Serrano; Rebecca Hu; Shay O'Neill; Chiuhui Mary Wang; Christopher Thrasivoulou; Kieran T Power; Alexis White; Thomas Serena; Anthony R J Phillips; David L Becker
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

Review 10.  Inhibitors of connexin and pannexin channels as potential therapeutics.

Authors:  Joost Willebrords; Michaël Maes; Sara Crespo Yanguas; Mathieu Vinken
Journal:  Pharmacol Ther       Date:  2017-07-15       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.